MAT
46
12
JWN
48
6
JPM
69
2
DHI
48
4
RSG
71
3
IPG
56
3
M
37
12
RIG
60
2
PAYX
53
2
KEY
46
3
WY
54
4
BBY
46
10
HD
57
2
MTB
67
2
ROST
63
12
UNP
52
7
VZ
50
3
GIS
31
3
LYB
39
2
TDC
80
4
MAT
46
12
JWN
48
6
JPM
69
2
DHI
48
4
RSG
71
3
IPG
56
3
M
37
12
RIG
60
2
PAYX
53
2
KEY
46
3
WY
54
4
BBY
46
10
HD
57
2
MTB
67
2
ROST
63
12
UNP
52
7
VZ
50
3
GIS
31
3
LYB
39
2
TDC
80
4
Financhill
Back

Monte Rosa Therapeutics 10K Form

Buy
55

GLUE
Monte Rosa Therapeutics

Last Price:
8.49
Seasonality Move:
7.5%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive GLUE News And Ratings

See the #1 stock for the next 7 days that we like better than GLUE

GLUE Financial Statistics

Sales & Book Value

Annual Sales: --
Cash Flow: $-21.39M
Price / Cash Flow: 0
Annual Sales: $3.35
Price / Book: 2.54

Profitability

EPS (TTM): -1.83000
Net Income (TTM): $-119.39M
Gross Margin: --
Return on Equity: 0%
Return on Assets: 0%

Monte Rosa Therapeutics Earnings Forecast

Key Monte Rosa Therapeutics Financial Ratios

  • The Interest Expense is -0.01% of Operating Income.
  • Per Share Earnings over the last 5 years have been positive in 1 years.

Monte Rosa Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: GLUE
Website: monterosatx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 6.03
Quick Ratio: 5.83

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

GLUE Technical Analysis vs Fundamental Analysis

Buy
55
Monte Rosa Therapeutics (GLUE) is a Buy

Is Monte Rosa Therapeutics a Buy or a Sell?